Two production bases (antibody drugs and recombinant protein drugs) of Jiangsu T-mab BioPharma Co., Ltd. are under construction and are expected to be completed by the end of 2018 and be ready for production in 2019. The total gross floor area of the production base exceeds 18,500 square meters and the total investment exceeds RMB 400 million. The production base is designed and constructed with reference to EU GMP, FDA cGMP and China GMP standards, and will meet the commercial production of antibody drugs and recombinant protein drugs.